Greg Cima

The firm is working on more assays to help decide which cancer patients are suitable for immunotherapies and hopes to establish a US-based lab in 2023.

The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.

US officials plan to create a fast lane for EUAs and help diagnostic companies navigate development challenges including assay validation.

Allergenis claims its assay results are more accurate than other first-line tests and give more details on the severity of immune response.

In the absence of more emergency funding, White House officials plan to shift COVID-19 diagnostics into the broader commercial healthcare system.

Research results suggest the cell-free DNA test could improve measures of disease progress and patient survivability, which could help doctors prolong patients' lives.

The company's Diagnostics and Genomics group's revenues were down 2 percent year over year, but up 3 percent on a core basis.

Nanopath's platform was the winner of AACC's Disruptive Technology Award, and the firm closed on a $10 million Series A financing round. 

The company is selling its applied, food, and enterprise services to New Mountain Capital for $2.45 billion in cash.